One of the greatest challenges in Alzheimer disease diagnosis is not simply identifying pathology, but ensuring patients have access to the tools needed to detect it. While amyloid PET imaging and cerebrospinal fluid testing have transformed the ability to confirm underlying disease biology, their cost, availability, and procedural requirements continue to limit widespread implementation across many clinical settings.
At the 2026 Alzheimer’s Association International Conference, investigators reported that P-tau217 blood-based assays met reliability criteria for noninferiority relative to amyloid PET quantitation in cognitively unimpaired individuals. The study involved various groups of people without clear cognitive symptoms, and the results indicated that the blood markers were just as effective at identifying biological markers associated with Alzheimer’s as the standard imaging scans.
Across independent cohorts, the assays demonstrated comparable positive predictive value-based agreement with amyloid PET. Such consistency is critical because it suggests that blood tests could reliably serve as a proxy for more expensive and invasive procedures in a wide range of clinical scenarios. Pivoting to prevention is particularly important as the medical community shifts toward early intervention strategies that aim to stop disease progression before symptoms become severe.
Data suggests blood tests match imaging. In a report from the outlet, Dr. Yogesh Shah discussed the implications of these results. Shah, who has been involved in Alzheimer care for more than 25 years, said the findings are exciting.
Related: User access denied after system block
“This is very exciting,” Shah stated. “It is the field we’ve been waiting for.”
He has always hoped for a day when a simple blood test could provide information comparable to amyloid PET or lumbar punctures. If performed properly in the right laboratory, Shah believes it could provide information that is as close to, or better than, amyloid PET results. This equivalence is the key to making the technology viable for routine use rather than just specialized research settings.
Shah pointed out that access to amyloid PET imaging remains limited in many parts of the United States. Even where imaging is available, it is expensive; scans can cost several thousand dollars. Obtaining insurance approval for these scans often requires significant time and effort from patients and clinical staff.
Lumbar punctures present similar challenges. While they are valuable diagnostic tools that can be performed in many centers, they still require specialized procedures, scheduling, and resources. The tests also carry the possibility of complications. Certain patients, such as those taking anticoagulants, may not be ideal candidates for this procedure.
Democratizing Alzheimer diagnosis is the next step. Shah explained that these findings have the potential to make AD diagnosis much more accessible. By removing the need for specialized facilities or complex procedures, the approach could allow more physicians to screen and identify patients who are showing early signs of the condition.
Related: User Account Blocked by Social Media Platform
The technology could democratize diagnosis by reducing barriers related to geography, cost, and healthcare access. For many older adults, the prospect of seeking a dementia evaluation is often overshadowed by the logistical hurdles of travel and the fear of invasive procedures. A simple blood draw in a local clinic would remove the need to visit specialized centers far from home and eliminate the anxiety associated with a spinal tap, potentially encouraging more people to seek help before symptoms worsen significantly.
Shah noted that many patients delay evaluation because of financial concerns or other social determinants of health. A blood test can be performed much more easily and in many more settings. In clinics like the one in Des Moines, Shah noted that mobile memory clinics are used to bring testing directly into the community rather than requiring patients to come to the center.
Shah believes the future will allow for the identification of many more individuals with AD and intervene earlier. Unfortunately, a substantial proportion of Americans with AD remain undiagnosed, even after symptoms develop. The gap is larger among those with mild cognitive impairment. Shah expressed hope that P-tau217 and other blood-based biomarkers will make Alzheimer disease diagnosis easier and more effective.
The report was independently produced by the outlet and supported by Eli Lilly and Company. Eli Lilly has no direct influence on the content itself.